En Carta Diagnostics has raised €5 million to support regulatory approval, manufacturing and commercial launch of its at-home molecular testing platform in Europe and the USA.

En Carta Diagnostics has secured €5 million in funding to accelerate development and commercialisation of its at-home molecular diagnostics platform, with plans to expand regulatory approvals, manufacturing and market access in Europe and the USA.

The financing includes €3 million in equity led by Blue Forest Ventures, with participation from Ring Capital, existing investors CentraleSupélec Venture, 50 Partners Health and a group of business angels. The round also includes €2 million in non-dilutive funding from Bpifrance and other partners.

The Paris-based diagnostics company said the investment will support three priorities: obtaining regulatory certification in Europe and the USA, scaling manufacturing through a partnership with Circum Medical, and preparing for the commercial launch of its molecular testing platform.

En Carta is initially targeting early diagnosis of Lyme disease before expanding into sexually transmitted infection screening, including tests for chlamydia and gonorrhoea.

The company is currently conducting two clinical trials of its lead Lyme disease diagnostic in Boston, USA, and Bialystok, Poland, following completion of its first-in-human study.

Earlier this year, En Carta received FDA Breakthrough Device Designation for its Lyme disease test, providing access to an accelerated regulatory pathway in the USA. The company also recently entered a co-development and commercialisation agreement with French diagnostics company AAZ to develop rapid molecular tests for sexually transmitted infections.

Unlike conventional molecular diagnostics, which typically require laboratory-based PCR testing, En Carta is developing a platform designed to deliver laboratory-quality molecular testing in a rapid, portable format suitable for use at home. The company said its technology can provide results in around 30 minutes while maintaining high analytical performance.

The platform is based on aptamer technology, which enables highly specific detection of molecular targets and could support future applications across infectious diseases and other diagnostic indications.

Guillaume Horreard, co-founder and chief executive officer of En Carta Diagnostics, said: “From FDA Breakthrough Designation to a €13 million commercial partnership, and now €5 nillion in financing, En Carta is delivering. Our next milestone is getting our two products, a rapid molecular diagnostic for Borrelia, the bacteria responsible for Lyme disease, and an STI screening test, into the hands of patients and clinicians across Europe and the US.

“This first closing brings us closer to our mission of transforming access to testing. By enabling patients to perform reliable molecular tests wherever they are, we can support earlier diagnosis, improve patient outcomes, and help relieve pressure on healthcare systems.”

Lyme disease is the most common vector-borne disease in the Northern Hemisphere, with an estimated 1.2 million cases reported each year. The disease is caused by Borrelia bacteria transmitted through tick bites, and early diagnosis remains challenging because existing diagnostic methods often cannot reliably detect infection immediately after exposure.

The company believes bringing molecular diagnostics closer to patients could help reduce delays in diagnosis and improve access to timely treatment, while supporting wider adoption of point-of-care and home-based testing technologies.

Max Narr, co-founder and general partner at Blue Forest Ventures, said: “Improving access to fast, reliable diagnosis is essential to delivering better healthcare outcomes. En Carta Diagnostics’ technology has the potential to significantly enhance early detection and bring high-quality molecular testing closer to patients. This aligns fully with our mission to support innovations that improve care pathways and patient access.”